Bayer transferred its US glyphosate business to a new company named Ruveon after securing a court victory and reaching a settlement in the glyphosate litigation. The spin‑off isolates the bulk of glyphosate‑related legal exposure from Bayer’s pharma operations, potentially protecting the group’s earnings and allowing sharper strategic focus. Bayer AG, the newly created Ruveon entity, US plaintiffs in glyphosate cancer cases, and the courts that approved the settlement. Ruveon will operate as an independent agrochemical business, may seek external funding or a partnership, while Bayer continues to monitor any residual litigation and evaluates further portfolio streamlining. Following a favorable court ruling and a multibillion‑dollar settlement, Bayer has transferred its US glyphosate operations to a newly formed company, Ruveon. The move seeks to shield Bayer’s core pharmaceutical division from ongoing cancer‑linked lawsuits while allowing the agrochemical unit to operate independently. Market watchers will monitor whether Ruveon remains a standalone entity or becomes a target for acquisition or partnership.
INTELLIGENCE
Social Pulse
AI estimate · not scraped